Autophagy-Inducing Compound Design for Selective CNS Therapy

The patent applies local quality by designing compounds with specific molecular structures (Formula I) that have enhanced properties for crossing the blood-brain barrier and targeting CNS tissues. The compounds contain specific functional groups and structural features that confer selective affinity for neural tissues, thereby improving therapeutic effectiveness specifically in the central nervous system while maintaining autophagy induction capability.

The patent employs parameter changes by modifying key molecular parameters of autophagy inducers, including molecular weight, lipophilicity, and structural configuration. These parameter optimizations enable the compounds to better penetrate the blood-brain barrier and achieve selective accumulation in CNS tissues, resolving the contradiction between general therapeutic effect and CNS-specific selectivity.

The patent applies segmentation by dividing the broad spectrum of autophagy-related diseases into specific categories (CNS diseases, viral infections, cancer, metabolic disorders). For each category, the patent optimizes compound properties to achieve selective targeting while maintaining the core autophagy induction mechanism. This allows the compound to cover multiple disease types with enhanced precision for each specific indication.

The patent employs universality by designing a core molecular scaffold (Formula I) that maintains universal autophagy induction capability across different disease types, while allowing for specific functional modifications that enable targeted action in different disease contexts. This multi-functional design achieves both broad coverage and disease-specific precision.